AOD9604

Summary

AOD9604 is a synthetic fragment of human growth hormone (amino acids 176‑191) investigated primarily as an anti‑obesity peptide. Classified among growth‑hormone‑derived lipolytic peptides, it is being studied for its ability to modulate fat metabolism and, in preclinical models, to support musculoskeletal repair. The compound remains investigational, with early‑phase clinical trials reported but no regulatory approval for any indication.

Mechanism of Action

The peptide corresponds to the C‑terminal 176‑191 segment of hGH, a region that retains lipolytic activity while lacking most growth‑promoting effects of the full hormone. Reported mechanisms include activation of the IGF‑1 signaling cascade, stimulation of satellite‑cell activity, and enhancement of fatty‑acid oxidation in adipose tissue. By engaging these pathways, AOD9604 is thought to increase breakdown of stored triglycerides and improve adipocyte function without markedly affecting linear growth.

What the Research Shows

Several reviews cite AOD9604 as a candidate anti‑obesity agent in clinical development. Wilding (2004) noted that Metabolic was conducting phase IIa studies, and Jensen (2006) reported that the peptide was undergoing clinical trials aimed at improving adipose‑tissue function and fatty‑acid metabolism. The orthopaedic peptide review (2026) described AOD9604 as a growth‑hormone secretagogue that activates IGF‑1 signaling and satellite‑cell repair, but emphasized that clinical trials are lacking. A sports‑medicine review (2026) highlighted favorable metabolic and tissue‑repair outcomes in animal models while stressing the scarcity of rigorous human safety data. Overall, the literature reflects early‑stage human investigations and preclinical evidence, with no large‑scale efficacy or safety trials published.

Reported Benefits

Preclinical data suggest AOD9604 can promote lipolysis, improve adipocyte metabolism, and modestly support musculoskeletal tissue repair through IGF‑1‑mediated pathways. Early‑phase human studies have been initiated to assess weight‑loss potential in overweight individuals, and the peptide is proposed to reduce adiposity without the growth‑stimulating effects of full‑length hGH. These putative benefits are derived from animal experiments and limited phase IIa observations; definitive clinical benefit has not yet been demonstrated.

Limitations of the Evidence

The evidence base is limited to early‑phase trials and animal studies; no large, randomized controlled trials have been published. Regulatory approval has not been granted, and the compound remains investigational. Reported data do not establish the magnitude or durability of weight loss, nor confirm efficacy for musculoskeletal indications. Safety profiling is incomplete, and the lack of robust human data creates uncertainty about optimal dosing, long‑term effects, and comparative advantage over existing anti‑obesity therapies.

Safety Considerations

Human safety data for AOD9604 are sparse. Reviews describe the peptide as unapproved and note that rigorous safety assessments in patients are lacking. Potential concerns include unknown adverse effects on metabolism, endocrine function, or tissue repair pathways, and the possibility of serious harm when used outside regulated settings. The sports‑medicine review warns that the “gray‑market” availability of unapproved peptides may expose users to contaminants or dosing errors. Until controlled clinical trials report systematic safety outcomes, caution is advised for any off‑label or self‑administered use.

How It Is Administered

AOD9604 has been investigated for administration via subcutaneous injection, nasal spray, and oral formulations. Specific dosing regimens, concentrations, or delivery devices are not detailed in the cited literature. As an investigational peptide, it is not available through approved pharmaceutical channels, and formulations used in research settings may differ from those marketed informally.

Routes of Administration

Goals & Uses

• Fat loss / lipolysisBody CompositionModerate
• Improved body compositionMetabolicLow
• Weight lossMetabolicModerateChronic weight management and appetite reduction
• Anti-lipogenic effectMetabolicModerate
• Cartilage and bone repairRegenerativeLow
• Metabolic syndrome improvementMetabolicLow

Contraindications

• Active malignancyOncologyHighUse caution or avoid depending on agent and context
• known hypersensitivity to peptideImmunologicModerate
• PregnancyPopulationHighPotential fetal risk or insufficient safety data
• Hypersensitivity to hGH fragmentsImmunologicalHigh

Adverse Effects

• Injection site reactionsLocalCommon
• HeadacheNeurologicUncommonPain in the head or upper neck
• FlushingVascularUncommonWarmth and redness of the skin
• Transient hyperglycemiaMetabolic/EndocrineRare
• NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
• Injection site erythemaLocalCommonRedness at the injection site

Drug Interactions

• InsulinModerateMay increase risk of low blood sugar
• Insulin / antidiabetic agentsLow
• Full-length recombinant human growth hormone (rhGH)Low
• Other GH analoguesModerate

Population Constraints

• Elderly (>65 years)AgeRelative
• Children (<18 y)AgeRelative
• Pediatric populationAgeAbsolute
• Lactating womenReproductiveAbsolute

Regulatory Status

• European UnionInvestigationalClinical trials conducted; no marketing authorization.
• United StatesInvestigationalInvestigational New Drug (IND) status; not FDA‑approved.
• United KingdomInvestigationalUsed only in research settings.

Not approved by FDA, EMA or MHRA. Clinical development halted in several jurisdictions; currently marketed only as a research chemical.

Evidence & Sources

• [Obesity: a review of currently used antiobesity drugs and new compounds in clinical development]
  Journal ArticleModerateZieba R2007-01-01T00:00:00.000000Z
• Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
  Journal ArticleModerateRahman OF, Lee SJ, Seeds WA2026-01-01T00:00:00.000000Z
• Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors
  Journal ArticleModerateJensen MD2006-01-01T00:00:00.000000Z
• AOD-9604 Metabolic
  Journal ArticleModerateWilding J2004-01-01T00:00:00.000000Z
• Current updates in the medical management of obesity
  Journal ArticleModerateKhan A, et al.2012-01-01T00:00:00.000000Z
• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
  Journal ArticleModerateMendias CL, Awan TM2026-01-01T00:00:00.000000Z

Frequently Asked Questions